Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Operations: 2010-2025

Historic Cash from Operations for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Cash from Operations rose 381.37% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.7 million, marking a year-over-year decrease of 45.49%. This contributed to the annual value of $103.5 million for FY2024, which is 43.55% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Cash from Operations stood at $47.6 million for Q3 2025, which was up 415.79% from -$15.1 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Cash from Operations ranged from a high of $80.2 million in Q1 2023 and a low of -$15.1 million during Q2 2025.
  • Its 3-year average for Cash from Operations is $30.9 million, with a median of $33.5 million in 2024.
  • The largest annual percentage gain for Ironwood Pharmaceuticals' Cash from Operations in the last 5 years was 381.37% (2025), contrasted with its biggest fall of 145.03% (2025).
  • Ironwood Pharmaceuticals' Cash from Operations (Quarterly) stood at $64.6 million in 2021, then rose by 22.63% to $79.2 million in 2022, then plummeted by 54.74% to $35.8 million in 2023, then tumbled by 57.54% to $15.2 million in 2024, then soared by 381.37% to $47.6 million in 2025.
  • Its Cash from Operations was $47.6 million in Q3 2025, compared to -$15.1 million in Q2 2025 and $20.0 million in Q1 2025.